Policy Changes on Pharmaceutical Advertising Under Consideration

On Wednesday, CNN reported that Health and Human Services (HHS) director Robert F. Kennedy Jr. is contemplating a significant change in the TV news industry, focusing on pharmaceutical advertising restrictions.

The changes could involve closing loopholes that allow pharmaceutical companies to treat their advertising costs as tax credits, which, according to CNN, might financially impact traditional media outlets.

Kennedy Jr. has consistently advocated against direct-to-consumer (DTC) drug advertising, a practice that is banned in nearly every other country. However, he believes that a complete ban may face challenges on First Amendment grounds.

In a tweet, Kennedy Jr. expressed his desire to bring former President Trump back to the White House, hinting at potential policy shifts regarding drug advertisements.

Reportedly, Kennedy Jr. aims to eliminate the tax credit loophole and requires advertisers to clearly outline the risks associated with their medications in advertisements, as stated by CNN. The current loophole is estimated to cost taxpayers over $1 billion annually, according to an analysis by the Sustainable RX Pricing Campaign.

Additionally, the same analysis revealed that pharmaceutical companies spent over $5 billion on TV advertising in 2024. Kennedy Jr. has found support in Congress, with a bipartisan group of House members introducing the Drug Advertising Handout Act to scrutinize DTC ads further.

Pharmaceutical ads represent a considerable share of primetime news programming. According to ISPOT analysis, drugmakers accounted for about 25% of advertising minutes on major networks like MSNBC, Fox News, and CNN.

However, CNN noted that Kennedy Jr.’s proposed policy could adversely affect the network, warning that eliminating direct drug ads could harm traditional broadcasters and cable companies.